Cargando…
Lipoxin A4 Ameliorates Imiquimod-Induced Psoriasis-Like Dermatitis via Promoting the Regression of Inflammation
INTRODUCTION: As a mediator of inflammation resolution, lipoxin A4 (LXA4) mainly plays an anti-inflammatory role and promotes inflammation resolution. LXA4 plays an inhibiting inflammatory role in a variety of diseases, tissues and cells, including keratinocytes. Psoriasis is a chronic inflammatory...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10422962/ https://www.ncbi.nlm.nih.gov/pubmed/37575152 http://dx.doi.org/10.2147/CCID.S418467 |
_version_ | 1785089342143725568 |
---|---|
author | Hu, Feng Qu, Zilu Chen, Kai Zhang, Ping Wang, Bei Jiang, Ruili Zuo, Yuyue Xia, Ping Chen, Hongxiang |
author_facet | Hu, Feng Qu, Zilu Chen, Kai Zhang, Ping Wang, Bei Jiang, Ruili Zuo, Yuyue Xia, Ping Chen, Hongxiang |
author_sort | Hu, Feng |
collection | PubMed |
description | INTRODUCTION: As a mediator of inflammation resolution, lipoxin A4 (LXA4) mainly plays an anti-inflammatory role and promotes inflammation resolution. LXA4 plays an inhibiting inflammatory role in a variety of diseases, tissues and cells, including keratinocytes. Psoriasis is a chronic inflammatory skin disease mediated by dysregulation of inflammation of immune cells and keratinocytes. However, the expression and role of LXA4 in psoriasis-like mouse models are still unclear. METHODS: Imiquimod (IMQ) topical treatment of dorsal skin induces psoriasis-like dermatitis in BALB/c mice, pretreated intraperitoneally with or without LXA4 prior to IMQ application. Severity of dorsal lesions is assessed by using a modified human scoring system and histopathology. The concentration of LXA4 and the expression of ALOX15 (a key gene in LXA4 metabolic synthesis) in lesional skins were detected by ELISA and Western blot. Quantitative PCR and ELISA were conducted to detect the mRNA and secretion levels of inflammatory cytokines. The proportion of IL-17A-producing γδT cells in skin and skin draining cervical lymph nodes and helper (Th) 17 cells in spleens was evaluated by flow cytometry. Western blotting was used to analyze the expressions of p-STAT3 and TRAF6. RESULTS: The concentration of LXA4 and the expression of ALOX15 were decreased in IMQ-induced lesional skin. LXA4 significantly relieved psoriasis-like lesions in IMQ-induced mouse models. Furthermore, LXA4 decreased IMQ-induced systemic inflammation, including reduced the proportion of IL-17A-producing gdT cells in skin and skin draining cervical lymph nodes and Th17 cells in spleens, the secretion and expression of CCL20, IL-17A, IL-1β, and TNF-α in skin and serum. LXA4 markedly inhibited IMQ-induced expression of TRAF6 and p-STAT3. CONCLUSION: LXA4 significantly ameliorates IMQ-induced psoriasis-like inflammation, and LXA4 can be used as a target for psoriasis treatment. |
format | Online Article Text |
id | pubmed-10422962 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-104229622023-08-13 Lipoxin A4 Ameliorates Imiquimod-Induced Psoriasis-Like Dermatitis via Promoting the Regression of Inflammation Hu, Feng Qu, Zilu Chen, Kai Zhang, Ping Wang, Bei Jiang, Ruili Zuo, Yuyue Xia, Ping Chen, Hongxiang Clin Cosmet Investig Dermatol Original Research INTRODUCTION: As a mediator of inflammation resolution, lipoxin A4 (LXA4) mainly plays an anti-inflammatory role and promotes inflammation resolution. LXA4 plays an inhibiting inflammatory role in a variety of diseases, tissues and cells, including keratinocytes. Psoriasis is a chronic inflammatory skin disease mediated by dysregulation of inflammation of immune cells and keratinocytes. However, the expression and role of LXA4 in psoriasis-like mouse models are still unclear. METHODS: Imiquimod (IMQ) topical treatment of dorsal skin induces psoriasis-like dermatitis in BALB/c mice, pretreated intraperitoneally with or without LXA4 prior to IMQ application. Severity of dorsal lesions is assessed by using a modified human scoring system and histopathology. The concentration of LXA4 and the expression of ALOX15 (a key gene in LXA4 metabolic synthesis) in lesional skins were detected by ELISA and Western blot. Quantitative PCR and ELISA were conducted to detect the mRNA and secretion levels of inflammatory cytokines. The proportion of IL-17A-producing γδT cells in skin and skin draining cervical lymph nodes and helper (Th) 17 cells in spleens was evaluated by flow cytometry. Western blotting was used to analyze the expressions of p-STAT3 and TRAF6. RESULTS: The concentration of LXA4 and the expression of ALOX15 were decreased in IMQ-induced lesional skin. LXA4 significantly relieved psoriasis-like lesions in IMQ-induced mouse models. Furthermore, LXA4 decreased IMQ-induced systemic inflammation, including reduced the proportion of IL-17A-producing gdT cells in skin and skin draining cervical lymph nodes and Th17 cells in spleens, the secretion and expression of CCL20, IL-17A, IL-1β, and TNF-α in skin and serum. LXA4 markedly inhibited IMQ-induced expression of TRAF6 and p-STAT3. CONCLUSION: LXA4 significantly ameliorates IMQ-induced psoriasis-like inflammation, and LXA4 can be used as a target for psoriasis treatment. Dove 2023-08-08 /pmc/articles/PMC10422962/ /pubmed/37575152 http://dx.doi.org/10.2147/CCID.S418467 Text en © 2023 Hu et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Hu, Feng Qu, Zilu Chen, Kai Zhang, Ping Wang, Bei Jiang, Ruili Zuo, Yuyue Xia, Ping Chen, Hongxiang Lipoxin A4 Ameliorates Imiquimod-Induced Psoriasis-Like Dermatitis via Promoting the Regression of Inflammation |
title | Lipoxin A4 Ameliorates Imiquimod-Induced Psoriasis-Like Dermatitis via Promoting the Regression of Inflammation |
title_full | Lipoxin A4 Ameliorates Imiquimod-Induced Psoriasis-Like Dermatitis via Promoting the Regression of Inflammation |
title_fullStr | Lipoxin A4 Ameliorates Imiquimod-Induced Psoriasis-Like Dermatitis via Promoting the Regression of Inflammation |
title_full_unstemmed | Lipoxin A4 Ameliorates Imiquimod-Induced Psoriasis-Like Dermatitis via Promoting the Regression of Inflammation |
title_short | Lipoxin A4 Ameliorates Imiquimod-Induced Psoriasis-Like Dermatitis via Promoting the Regression of Inflammation |
title_sort | lipoxin a4 ameliorates imiquimod-induced psoriasis-like dermatitis via promoting the regression of inflammation |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10422962/ https://www.ncbi.nlm.nih.gov/pubmed/37575152 http://dx.doi.org/10.2147/CCID.S418467 |
work_keys_str_mv | AT hufeng lipoxina4amelioratesimiquimodinducedpsoriasislikedermatitisviapromotingtheregressionofinflammation AT quzilu lipoxina4amelioratesimiquimodinducedpsoriasislikedermatitisviapromotingtheregressionofinflammation AT chenkai lipoxina4amelioratesimiquimodinducedpsoriasislikedermatitisviapromotingtheregressionofinflammation AT zhangping lipoxina4amelioratesimiquimodinducedpsoriasislikedermatitisviapromotingtheregressionofinflammation AT wangbei lipoxina4amelioratesimiquimodinducedpsoriasislikedermatitisviapromotingtheregressionofinflammation AT jiangruili lipoxina4amelioratesimiquimodinducedpsoriasislikedermatitisviapromotingtheregressionofinflammation AT zuoyuyue lipoxina4amelioratesimiquimodinducedpsoriasislikedermatitisviapromotingtheregressionofinflammation AT xiaping lipoxina4amelioratesimiquimodinducedpsoriasislikedermatitisviapromotingtheregressionofinflammation AT chenhongxiang lipoxina4amelioratesimiquimodinducedpsoriasislikedermatitisviapromotingtheregressionofinflammation |